Matthew R. Wright

Matthew R. Wright

Auto-generated profile, based on publicly available information

Matthew R. Wright

Amgen Inc., 1120 Veterans Boulevard, South San Francisco, CA 94080, USA

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
XLXingrong Liu
Xingrong Liu
MWMatthew Wright
Matthew Wright
CHCornelis E. C. A. Hop
Cornelis E. C. A. Hop

24 January 2001 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DPDonald J. P. Pinto
Donald J. P. Pinto
MOMichael J. Orwat
Michael J. Orwat
SWShuaige Wang
Shuaige Wang
JFJohn M. Fevig
John M. Fevig
MQMimi L. Quan
Mimi L. Quan
PLPatrick Y. S. Lam
Patrick Y. S. Lam

1 October 2019 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
PDF file
DZDonglu Zhang
Donglu Zhang
CHCornelis E.C.A. Hop
Cornelis E.C.A. Hop
GPGabriela Patilea-Vrana
Gabriela Patilea-Vrana
GGGautham Gampa
Gautham Gampa
HSHerana Kamal Seneviratne
Herana Kamal Seneviratne
CKCyrus Khojasteh
Cyrus Khojasteh
The well accepted “free drug hypothesis” for small-molecule drugs assumes that only the free (unbound) drug concentration at the therapeutic target can elicit a pharmacologic effect. Unbound (free) drug concentrations in plasma are readily measurable and are often used as surrogates for the drug concentrations at the site of pharmacologic action in pharmacokinetic-pharmacodynamic analysis and clinical dose projection in drug discovery. Furthermore, for permeable compounds at pharmacokinetic steady state, the free drug concentration in tissue is likely a close approximation of that in plasma; however, several factors can create and maintain disequilibrium between the free drug concentration in plasma and tissue, leading to free drug concentration asymmetry. These factors include drug uptake and extrusion mechanisms involving the uptake and efflux drug transporters, intracellular biotransformation of prodrugs, membrane receptor–mediated uptake of antibody-drug conjugates, pH gradients, unique distribution properties (covalent binders, nanoparticles), and local drug delivery (e.g., inhalation). The impact of these factors on the free drug concentrations in tissues can be represented by Kp,uu, the ratio of free drug concentration between tissue and plasma at steady state. This review focuses on situations in which free drug concentrations in tissues may differ from those in plasma (e.g., Kp,uu > or <1) and discusses the limitations of the surrogate approach of using plasma-free drug concentration to predict free drug concentrations in tissue. This is an important consideration for novel therapeutic modalities since systemic exposure as a driver of pharmacologic effects may provide limited value in guiding compound optimization, selection, and advancement. Ultimately, a deeper understanding of the relationship between free drug concentrations in plasma and tissues is needed.

17 September 2003 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PLPatrick Y. S. Lam
Patrick Y. S. Lam
CCCharles G. Clark
Charles G. Clark
RLRenhua Li
Renhua Li
DPDonald J. P. Pinto
Donald J. P. Pinto
MOMichael J. Orwat
Michael J. Orwat
RWRuth R. Wexler
Ruth R. Wexler

1 July 1999 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MQMimi L. Quan
Mimi L. Quan
CEChristopher D. Ellis
Christopher D. Ellis
ALAnn Y. Liauw
Ann Y. Liauw
RARichard S. Alexander
Richard S. Alexander
RKRobert M. Knabb
Robert M. Knabb
RWRuth R. Wexler
Ruth R. Wexler

29 October 2003 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JPJames R. Pruitt
James R. Pruitt
DPDonald J. P. Pinto
Donald J. P. Pinto
RGRobert A. Galemmo
Robert A. Galemmo
RARichard S. Alexander
Richard S. Alexander
KRKaren A. Rossi
Karen A. Rossi
RWRuth R. Wexler
Ruth R. Wexler